NCT00652873View on ClinicalTrials.gov

Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fed Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2001

Primary Completion Date

December 31, 2001

Study Completion Date

December 31, 2001

Conditions
To Determine Bioequivalence Under Fed Conditions
Interventions
DRUG

Cabergoline

Tablets 0.5 mg (2 x 0.5 mg dose), fed

DRUG

Dostinex

Tablets, 0.5 mg (2 X 0.5 mg dose), fed

Trial Locations (1)

G1V 2K8

Anapharm, Inc., Sainte-Foy

Sponsors

Collaborators (1)

Anapharm
All Listed Sponsors
collaborator

Anapharm

INDUSTRY

lead

Par Pharmaceutical, Inc.

INDUSTRY

NCT00652873 - Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fed Conditions | Biotech Hunter | Biotech Hunter